AVGO vs DBD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Compare Another Pair
Related Comparisons
AVGO vs DBD: Head-to-Head Comparison
This page compares Broadcom Inc. (AVGO) and Diebold Nixdorf, Incorporated (DBD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.